Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback